Real-time Estimate
Cboe BZX
03:02:20 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
6.845
USD
|
-6.62%
|
|
-10.45%
|
-38.71%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
28.38
|
417
|
363.1
|
808.4
|
604.4
|
519.7
|
-
|
-
|
Enterprise Value (EV)
1 |
28.38
|
417
|
363.1
|
697.3
|
469.3
|
455.8
|
263.1
|
376.2
|
P/E ratio
|
-1.18
x
|
-5.91
x
|
-3.9
x
|
-9.09
x
|
-6.78
x
|
-8.71
x
|
-5.82
x
|
-4.13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.89
x
|
50.9
x
|
82.3
x
|
-11,889
x
|
1,419
x
|
16.6
x
|
20.8
x
|
-
|
EV / Revenue
|
4.89
x
|
50.9
x
|
82.3
x
|
-10,255
x
|
1,102
x
|
14.6
x
|
10.5
x
|
-
|
EV / EBITDA
|
-
|
-
|
-3.77
x
|
-7.93
x
|
-
|
-4.78
x
|
-2.39
x
|
-3.13
x
|
EV / FCF
|
-
|
-12
x
|
-4.02
x
|
-11.1
x
|
-6.19
x
|
-5.68
x
|
-2.56
x
|
-2.29
x
|
FCF Yield
|
-
|
-8.31%
|
-24.9%
|
-8.99%
|
-16.2%
|
-17.6%
|
-39.1%
|
-43.7%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
15,015
|
36,968
|
39,644
|
49,146
|
53,729
|
70,902
|
-
|
-
|
Reference price
2 |
1.890
|
11.28
|
9.160
|
16.45
|
11.25
|
7.330
|
7.330
|
7.330
|
Announcement Date
|
3/27/20
|
2/25/21
|
3/15/22
|
2/28/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5.801
|
8.185
|
4.41
|
-0.068
|
0.426
|
31.25
|
25
|
-
|
EBITDA
1 |
-
|
-
|
-96.36
|
-87.94
|
-
|
-95.37
|
-110
|
-120.3
|
EBIT
1 |
-21.46
|
-54.8
|
-85.54
|
-87.74
|
-83.51
|
-61.74
|
-109
|
-179
|
Operating Margin
|
-370%
|
-669.5%
|
-1,939.62%
|
129,029.41%
|
-19,603.29%
|
-197.55%
|
-435.86%
|
-
|
Earnings before Tax (EBT)
1 |
-20.58
|
-54.46
|
-97.09
|
-84.91
|
-88.45
|
-49.07
|
-141.6
|
-180.2
|
Net income
1 |
-20.52
|
-49.04
|
-97.09
|
-84.71
|
-88.45
|
-59.05
|
-141.6
|
-180.2
|
Net margin
|
-353.71%
|
-599.2%
|
-2,201.43%
|
124,577.94%
|
-20,762.21%
|
-188.96%
|
-566.4%
|
-
|
EPS
2 |
-1.600
|
-1.910
|
-2.350
|
-1.810
|
-1.660
|
-0.8417
|
-1.260
|
-1.775
|
Free Cash Flow
1 |
-
|
-34.64
|
-90.36
|
-62.71
|
-75.86
|
-80.3
|
-102.8
|
-164.3
|
FCF margin
|
-
|
-423.22%
|
-2,048.7%
|
92,223.53%
|
-17,806.81%
|
-256.94%
|
-411.33%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
2/25/21
|
3/15/22
|
2/28/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3.278
|
0.032
|
0.008
|
0.002
|
-0.11
|
0.021
|
0.006
|
0.362
|
0.037
|
0.005
|
0.00062
|
31.25
|
0.00125
|
-
|
-
|
EBITDA
1 |
-23.87
|
-19.38
|
-20.34
|
-24.89
|
-23.27
|
-21.4
|
-17.5
|
-21.99
|
-
|
-
|
-19.9
|
-20.4
|
-20.9
|
-
|
-
|
EBIT
1 |
-20.68
|
-19.5
|
-20.4
|
-24.75
|
-23.09
|
-21.76
|
-18.01
|
-22.54
|
-21.2
|
-26.79
|
-25.23
|
15.28
|
-25.13
|
-28.21
|
-32.94
|
Operating Margin
|
-631.08%
|
-60,934.38%
|
-254,937.5%
|
-1,237,600%
|
20,994.55%
|
-103,614.29%
|
-300,116.67%
|
-6,226.52%
|
-57,308.11%
|
-535,880%
|
-4,069,785.48%
|
48.91%
|
-2,010,026.4%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-23.89
|
-19.43
|
-20.11
|
-23.71
|
-21.66
|
-20.07
|
-16.06
|
-20.67
|
-31.64
|
-24.39
|
-24.17
|
24.43
|
-24.54
|
-25.7
|
-30.4
|
Net income
1 |
-23.89
|
-19.43
|
-20.11
|
-23.52
|
-21.66
|
-20.07
|
-16.06
|
-20.67
|
-31.64
|
-24.39
|
-24.78
|
15.65
|
-25.28
|
-25.7
|
-30.4
|
Net margin
|
-728.85%
|
-60,718.75%
|
-251,337.5%
|
-1,175,800%
|
19,690.91%
|
-95,590.48%
|
-267,683.33%
|
-5,710.22%
|
-85,516.22%
|
-487,880%
|
-3,996,237.1%
|
50.07%
|
-2,022,760%
|
-
|
-
|
EPS
2 |
-0.5700
|
-0.4400
|
-0.4200
|
-0.4800
|
-0.4400
|
-0.4000
|
-0.3200
|
-0.3900
|
-0.5400
|
-0.3400
|
-0.3450
|
0.1867
|
-0.3450
|
-0.3433
|
-0.3533
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/15/22
|
5/12/22
|
8/11/22
|
11/10/22
|
2/28/23
|
5/11/23
|
8/10/23
|
11/7/23
|
3/27/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
111
|
135
|
63.9
|
257
|
143
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-34.6
|
-90.4
|
-62.7
|
-75.9
|
-80.3
|
-103
|
-164
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.2
|
12.1
|
0.13
|
0.05
|
0.15
|
0.5
|
2.5
|
Capex / Sales
|
-
|
2.49%
|
274.74%
|
-185.29%
|
11.03%
|
0.48%
|
2%
|
-
|
Announcement Date
|
3/27/20
|
2/25/21
|
3/15/22
|
2/28/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
7.33
USD Average target price
20.57
USD Spread / Average Target +180.65% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.71% | 520M | | +9.86% | 118B | | +9.93% | 106B | | -11.18% | 23.4B | | -1.69% | 22.1B | | -10.23% | 18.34B | | -41.92% | 16.59B | | -15.59% | 15.97B | | +6.69% | 14.03B | | +16.32% | 11.67B |
Bio Therapeutic Drugs
|